Ken-ichi Ogawara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7806934/publications.pdf

Version: 2024-02-01

		1478505	1872680	
7	489	6	6	
papers	citations	h-index	g-index	
7 all docs	7 docs citations	7 times ranked	815 citing authors	

#	ARTICLE	IF	CITATIONS
1	Toward the schematization of the factors which affect the enhanced permeability and retention effect. Drug Delivery System, 2018, 33, 105-114.	0.0	0
2	A novel approach to overcome multidrug resistance: Utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors. European Journal of Pharmaceutical Sciences, 2014, 62, 274-280.	4.0	15
3	PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. International Journal of Pharmaceutics, 2011, 412, 132-141.	5.2	121
4	In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. Journal of Controlled Release, 2009, 133, 4-10.	9.9	91
5	Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. International Journal of Pharmaceutics, 2008, 353, 28-34.	5.2	72
6	Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. International Journal of Pharmaceutics, 2008, 359, 234-240.	5.2	78
7	Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. International Journal of Pharmaceutics, 2008, 359, 272-279.	5.2	112